Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Cancer Prevention Month: Get ACRO Health Gift Cards! Cancer Prevention Month: Get ACRO Health Gift Cards!
Fill out organ-on-a-chip questionnaire to win a FREE gift! Fill out organ-on-a-chip questionnaire to win a FREE gift!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
FACS analysis of FcRn (FCGRT & B2M) on HEK293/Human FcRn (FCGRT & B2M) Stable Cell Line.
FACS assay shows that FITC-Labeled Human IgG1 Fc (C103S, M135Y, S137T, T139E, H316K, N317F) Protein, His Tag (Cat. No. IG1-HF2H3) can bind to HEK293/Human FcRn (FCGRT & B2M) Stable Cell Line. HEK293/Human FcRn (FCGRT & B2M) Stable Cell Line was red line, negative control HEK293 cells was grey line(QC tested).
Human IgG1 Fc (C103S, M135Y, S137T, T139E, H316K, N317F), His Tag (Cat. No. IG1-H52H8) immobilized on CM4 Chip can bind Human FCGRT&B2M Heterodimer Protein, Strep Tag&Tag Free (Cat. No. FCM-H5283) with an affinity constant of 23.8 nM as determined in a SPR assay (Biacore 8K) (QC tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Efgartigimod alfa | ARGX-113; EFG PH20 | Approved | Argenx Se | Vyvgart, 卫伟迦, VYVGART, VYVGART HYTRULO | United States | Myasthenia Gravis | Argenx BV | 2021-12-17 | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic; Myasthenia Gravis; Nephrosis; Polyneuropathies; Sjogren's Syndrome; Postural Orthostatic Tachycardia Syndrome; Autoimmune Diseases; Glomerulonephritis, Membranous; Lupus Nephritis; Pemphigoid, Bullous; Nephrotic Syndrome; Thrombocytopenia; Guillain-Barre Syndrome; Pemphigus; Tachycardia | Details |
Efgartigimod alfa/Hyaluronidase | Approved | Argenx BV | VYVGART HYTRULO | United States | Myasthenia Gravis | Argenx BV | 2023-06-20 | Myasthenia Gravis | Details | |
Rozanolixizumab | UCB-7665 | Approved | Ucb Sa | RYSTIGGO | United States | Myasthenia Gravis | Ucb Inc | 2023-06-27 | Purpura, Thrombocytopenic, Idiopathic; Myasthenia Gravis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Thrombocytopenia; Glioma; Encephalitis; Fibromyalgia | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
IMVT-1402 | HL-161 ANS; IMVT-1402 | Phase 1 Clinical | Immunovant Sciences Gmbh, HanAll Biopharma Co Ltd | Autoimmune Diseases | Details |
Nipocalimab | M-281; JNJ-80202135 | Phase 3 Clinical | Momenta | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Myasthenia Gravis; Hemolysis; Myositis; Arthritis, Rheumatoid; Sjogren's Syndrome; Lupus Nephritis; Anemia, Hemolytic, Autoimmune; Lupus Erythematosus, Systemic; Pemphigoid, Bullous | Details |
This web search service is supported by Google Inc.